1y return+144.8%S&P 500 +20.9%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since March 31, 2024: $232 against $143 in the S&P 500.2
Patient Square Capital LPS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| Roivant Sciences LtdCUSIP G76279101 | $283.9M | 44.0% | −1.8% |
| RVMDRevolution Medicines Inc | $51.7M | 8.0% | New |
| MIRMMirum Pharmaceuticals Inc | $30.5M | 4.7% | +13.3% |
| ABVXAbivax Sa | $27.5M | 4.3% | +70.3% |
| ONCBeone Medicines Ltd | $25.7M | 4.0% | +11.8% |
| Pharvaris N VCUSIP N69605108 | $23.2M | 3.6% | +36.1% |
| ARGXArgenx Se | $21.3M | 3.3% | −37.4% |
| UTHRUnited Therapeutics Corp Del | $20.1M | 3.1% | New |
| BLTEBelite Bio Inc | $16.9M | 2.6% | −5.7% |
| COGTCogent Biosciences Inc | $16.4M | 2.5% | −28.7% |
| DBVTDbv Technologies S A | $14.9M | 2.3% | +31.1% |
| XENEXenon Pharmaceuticals Inc | $13.3M | 2.1% | −3.1% |
| BNTXBiontech Se | $12.5M | 1.9% | New |
| RCUSArcus Biosciences Inc | $11.0M | 1.7% | +82.5% |
| ELVNEnliven Therapeutics Inc | $10.8M | 1.7% | +6.2% |
| DNTHDianthus Therapeutics Inc | $10.5M | 1.6% | +15.0% |
| ALLOAllogene Therapeutics Inc | $10.5M | 1.6% | +46.4% |
| EYPTEyepoint Inc | $10.3M | 1.6% | −9.4% |
| ARQTArcutis Biotherapeutics Inc | $9.7M | 1.5% | −7.6% |
| CCCCC4 Therapeutics Inc | $7.5M | 1.2% | New |
| IVAInventiva Sa | $7.4M | 1.2% | New |
| KYMRKymera Therapeutics Inc | $5.4M | 0.8% | −52.5% |
| FTHFaeth Therapeutics Inc | $4.4M | 0.7% | New |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| Roivant Sciences LtdCUSIP G76279101 | December 31, 2022 | +342.9% | $283.9M |
| KYMRKymera Therapeutics Inc | March 31, 2025 | +319.0% | $5.4M |
| MIRMMirum Pharmaceuticals Inc | December 31, 2024 | +183.1% | $30.5M |
| DNTHDianthus Therapeutics Inc | September 30, 2025 | +147.7% | $10.5M |
| ELVNEnliven Therapeutics Inc | September 30, 2024 | +98.7% | $10.8M |
| Pharvaris N VCUSIP N69605108 | September 30, 2024 | +86.7% | $23.2M |
| EYPTEyepoint Inc | September 30, 2024 | +79.0% | $10.3M |
| ARGXArgenx Se | June 30, 2025 | +68.3% | $21.3M |
| ABVXAbivax Sa | September 30, 2025 | +57.0% | $27.5M |
| XENEXenon Pharmaceuticals Inc | December 31, 2025 | +34.7% | $13.3M |
Sold off last quarter
- INSMInsmed Inc was $25.8M
- LEGNLegend Biotech Corp was $17.9M
- NKTRNektar Therapeutics was $15.1M
- CELCCelcuity Inc was $10.8M
- MRKMerck & Co Inc was $9.6M
- CATXPerspective Therapeutics Inc was $6.8M
- DFTXDefinium Therapeutics Inc was $6.3M
- HROWHarrow Inc was $5.8M
- TARAProtara Therapeutics Inc was $5.4M
- CTMXCytomx Therapeutics Inc. was $5.1M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +16.8% | +14.8% |
| March 31, 2026 | +14.6% | −4.6% |
| December 31, 2025 | +36.1% | +2.4% |
| September 30, 2025 | +34.4% | +7.8% |
| June 30, 2025 | +13.7% | +10.5% |
| March 31, 2025 | −10.8% | −4.6% |
| December 31, 2024 | +3.1% | +2.1% |
| September 30, 2024 | −1.2% | +5.4% |
| June 30, 2024 | −8.3% | +4.0% |
| December 31, 2023 | +0.5% | +11.2% |
| September 30, 2023 | −11.4% | −3.6% |
| June 30, 2023 | +18.0% | +8.3% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Patient Square Capital LP Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1819257&type=13F-HR&dateb=&owner=include&count=40CIK 1819257
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1819257/000181925726000005/Filed August 12, 2026 · accession 0001819257-26-000005